Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications

PR-104A is a dual hypoxia/nitroreductase gene therapy prodrug by virtue of its ability to undergo either one- or two-electron reduction to its cytotoxic species. It has been evaluated extensively in pre-clinical GDEPT studies, yet off-target human aldo-keto reductase AKR1C3-mediated activation has l...

詳細記述

書誌詳細

出版年:	Pharmaceuticals
主要な著者:	Amir Ashoorzadeh, Alexandra M. Mowday, Christopher P. Guise, Shevan Silva, Matthew R. Bull, Maria R. Abbattista, Janine N. Copp, Elsie M. Williams, David F. Ackerley, Adam V. Patterson, Jeff B. Smaill
フォーマット:	論文
言語:	英語
出版事項:	MDPI AG 2022-02-01
主題:	nitrobenzamide mustard prodrug SAR bystander effect cancer gene therapy
オンライン･アクセス:	https://www.mdpi.com/1424-8247/15/2/185